An interventional study of Eccentric training and Concentric training in Multiple Sclerosis, Rehabilitation and Neuro-Degenerative Disease, sponsored by University of Liege. Active, not recruiting at 1 site in Belgium. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by University of Liege · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 157 studies in Multiple Sclerosis with a site in Belgium — 14 open to participants now, 30 under way, 10 of them phase 3. Multiple Sclerosis · Belgium.
Among the 157 studies in Multiple Sclerosis with a site in Belgium, this one is the 96th largest by planned enrollment of the 132 interventional ones that give a count, is one of 5 that started in 2026, is one of 47 with no phase, reaches primary completion later than 11 of the 29 other live ones, and was the 153rd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →14 of the 157 studies in Multiple Sclerosis with a site in Belgium are open now. Recruiting first, the newest first:
Daphne Kos · Sites in Belgium, Denmark
Ages 18+
Sanofi · Sites in Belgium, United States, Brazil and 4 more countries
Ages 18–60
Hasselt University · Sites in Belgium
Ages 18–65 · Healthy volunteers
Novartis Pharmaceuticals · Sites in Belgium, United States, Argentina and 33 more countries
Ages 18–65
Hasselt University · Sites in Belgium, Italy, Spain
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
157 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 19 · Phase 3 53 · Phase 4 11
First in 1999; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 163 across the 132 interventional studies, 100 across the 25 observational. Of the 122 that completed or were terminated, 55 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 157 have an industry lead sponsor. The 10 most frequent:
University of Liege is the lead sponsor of 252 studies on the registry; 50 are open to participants now.
University of Liege has 2 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Multiple Sclerosis with a site in Belgium that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT07316764University of LiegeEccentric Cycling in Multiple Sclerosis Rehabilitation | 2026-12-30 |
| NCT05893225University Hospital, AntwerpMetformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration | 2027-02-28 |
| NCT05704361Hoffmann-La RocheA Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis | 2027-07-08 |
Add all 8 to your calendar (.ics) → With an account.
Among the 157 studies in Multiple Sclerosis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The project aims to optimise functional rehabilitation programmes for people with multiple sclerosis.
Investigators are proposing eccentric cycling as a new exercise modality for treating these patients.
Based on previous results in healthy subjects, investigators will attempt to define the optimal parameters of this new modality (in terms of duration, intensity, frequency, etc.).
Investigators also aim to demonstrate the effectiveness of this training (compared to conventional training) in improving muscle function, functional capacity, perception of chronic fatigue, quality of life, physical condition, and neurological and cognitive function.
Our study will focus on multiple sclerosis. For each pathology included, a "control" group will consist of patients undergoing a traditional rehabilitation program combined with a concentric cycling session. An experimental group ("eccentric rehabilitation") will consist of patients enrolled in an eccentric ergocycle training protocol paired with standard rehabilitation. In practice, a portion of the classical rehabilitation program will be replaced by either concentric or eccentric cycling, for a maximum duration of 30 minutes. Based on a preliminary study conducted in healthy subjects, a review of the existing literature, and a sample size calculation performed by the Biostatistics Department of the University Hospital of Liège, investigators aim to recruit 60 to 80 subjects per pathology (details in the appendix). Participation of pregnant women is permitted.
Type of Study
This is a prospective interventional study conducted longitudinally, with all subjects evaluated over the same time period (2025-2027). The study will take place at the Sart-Tilman sites (Blanc-Gravier, Exercise Physiology Unit) or at the CNRF in Fraiture-en-Condroz, depending on participant preference.
Neurological Pathologies Inclusion criteria
Participants must:
present with one of the following neurological disorders: Parkinson's disease or multiple sclerosis.
I. Eccentric Rehabilitation Program
Given the increasing clinical interest in eccentric contraction modalities for chronic diseases, a semi-recumbent eccentric ergometer has been specifically designed for clinical use. Patient installation on this device is safe and easily achievable, and the semi-recumbent position provides additional comfort during exercise. The ergometer allows secure workload control via visual feedback powered by dedicated software. The device can be transported between sites (Sart-Tilman - Fraiture - Esneux).
Experimental Protocol
This experimental study aims to establish and compare the effects of an eccentric cycling training protocol versus a traditional concentric cycling protocol performed on an ergometric bicycle. Subjects will be randomly allocated (stratified by sex and disease stage) into one of the two experimental groups. Randomization will be conducted by Mr. Benoît Vandenbroeck after encoding the relevant data in a table and assigning subjects within each stratum using random distribution.
Ambulatory participants will undergo a 2-week evaluation period followed by a 12-week training program consisting of two sessions per week, for a total of 28 sessions. In-hospitalisation participants will undergo a 1-week evaluation period (3 sessions), followed by 12 cycling training sessions and a 3 last sessions of evaluation, over a 4-week period, for a total of 18 sessions. Sessions will take place either at the Neurological and Functional Rehabilitation Center in Fraiture-en-Condroz (CNRF) or at Blanc-Gravier (Sart-Tilman), according to participant preference. Training sessions (eccentric or concentric) will last a maximum of 30 minutes. For participants already enrolled in a rehabilitation program at the CNRF, part of their traditional session will be replaced by the cycling training.
The unusual nature of eccentric training may induce mild delayed-onset muscle soreness (DOMS), including pain and stiffness, appearing 24-48 hours after exercise. These symptoms are transient, and symptomatic treatments (analgesics, stretching, ice) are not permitted.
Multiple variables will be assessed before, during, and after the intervention period to quantify potential effects of each training protocol and allow direct comparison.
Description of Study Phases
The study consists of 5 phases over a 12-week period for ambulatory participants and a 4-week period for in-hospitalisation participants (see appendix):
Phase 0: Baseline Testing
Out participants : Measurements will be collected 5-7 days before and 7-14 days after the training period to monitor longitudinal changes and evaluate the impact of the protocols on body composition and functional capacity.
In participants : Measurements will be collected the fisrt and lest (4th) week of the training program.
Eccentric Ergocycle Training Protocol Phase 1: Familiarization (4 weeks)
Out participants:
Two sessions per week for four weeks.
In participants:
Three sessions per week for two weeks. The main objective is to familiarize subjects with eccentric cycling and its specific neuromuscular demands, thus limiting potential muscle damage. Duration and intensity will gradually increase. To progress to the training phase, subjects must maintain an average power output within ±10% of their target theoretical power during the final familiarization session. If needed, one to two additional weeks of familiarization may be added. Beyond this point, participants unable to meet the criteria will be withdrawn from the study.
Phase 2: Training (Part 1 - 4 weeks)
Out:
These four weeks establish the first phase of training, with predefined duration and intensity levels.
In:
Two weeks with three training a week, with predefined duration and intensity levels.
Phase 3: Training (Part 2 - 4 weeks)
Out:
An additional four weeks are included, based on evidence showing greater benefits after 8-12 weeks of training. Intensity will be increased during this phase.
In:
An additional week (with three sessions) is included with an increased intensity.
Throughout the 12-week training period, temporal progression and identification of potential physiological adaptations will be monitored.
Phase 4: Final Testing
Out:
Participants will return to the laboratory twice to repeat the baseline assessments. These tests will be performed 7-10 days after the final training session to ensure adequate muscle recovery.
In:
Participants will take the three last evaluation sessions during the last (4th) week of the program.
The criteria were revised on the registry on Oct 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Eccentric training
Other: Concentric training
Eccentric cycling training
Concentric cycling training
Maximal Isometric Force
Maximal Isometric Force (in Newton-meters - Nm) of the quadriceps will be measured using a fixed dynamometer (Kinvent), at 90 degrees of knee flexion.
Time frame: At baseline and endline of intervention (Week 1 and 14)
Walking distance
6 minutes walking test and 2 minutes walking test will be performed to measure the walking capacities (in meters) of participants.
Time frame: At baseline and endline of intervention (Week 1 and 14)
Glial Fibrillary Acidic Protein (GFAP)
Blood samples will be collected to analyse GFAP concentration. This specific biomarker reflect chronic astrocytic activation, glial scarring, and track Progression Independent of Relapse Activity (PIRA) as well as diffuse, underlying neurodegeneration.
Time frame: At baseline and endline of intervention (Week 1 and 4)
Neurofilament Light Chain (NfL)
NfL is a structural component of nerve fibers (axons). Elevated levels in the blood reflect acute axonal injury, focal inflammatory activity, and help predict upcoming relapses.
Time frame: At baseline and endline of intervention (week 1 and 4)
Handgrip strength
Handgrip strength (in kilograms) will be measured using a handheld dynamometer.
Time frame: At baseline and endline of intervention (Week 1 and 14)
Spasticity
Spasticity will be evaluated using the Tardieu's scale of spasticity (expressed in arbitrary unit). This scale ranges from 0 (no resistance) to 4 (immobile)
Time frame: At baseline and endline of intervention (Week 1 and 14)
Timed up and go
The TUAG (in seconds) will be used to evaluate lower limb functional capacity
Time frame: At baseline and endline of intervention (Week 1 and 14)
Neurocognitive capacity
Neurocognitive capacity will be evaluated using a combinaison of Tests of Attentional Performance battery (TAP battery)
Time frame: At baseline and endline of intervention (Week 1 and 14)
Berg Balance Scale
The balance test will be used to evaluate balance capacity (expressed in arbitrary unit). This scale ranges from 0 (High fall risk) to 56 (no fall risk)
Time frame: At baseline and endline of intervention (Week 1 and 14)
Five time sit to stand test
The sit to stand test (in seconds) will be performed to measure lower limb functional capacity
Time frame: At baseline and endline of intervention (Week 1 and 14)
Maximal aerobic power
Maximal aerobic power (in Watts) will be evaluated by performing a Cardiopulmonary Exercise Test on an ergocycle.
Time frame: At baseline and endline of intervention (Week 1 and 14)
Maximal oxygen consumption
Oxygen consumption (in milliliter per minute per kilogram ) will be evaluated by performing a cardiopulmonary exercise test on an ergometer.
Time frame: At baseline and endline of intervention (Week 1 and 14)
Fatigue
Fatigue will be evaluated using the modified fatigue impact scale (MFIS) (expressed in arbitrary unit). This scale present different item that should be ranged from 0 (never) to 4 (always). We will collect the physical aspect with a maximal score ranginig from 0 (no fatigue) to 36 (exhausted)
Time frame: At baseline and endline of intervention (Week 1 and 14)
Multiple Sclerosis Quality of Life-54
Quality of life will be evaluated using the Multiple Sclerosis Quality of Life-54 (MSQoL-54). This scale will be expressed in percent.
Time frame: At baseline and endline of intervention (Week 1 and 14)
Maximal heart rate
Maximal heart brate (in beats per minute) will be measured by performing a cardiopulmonary exercise test on an ergocycle.
Time frame: At baseline and endline of intervention (Week 1 and 14)
Posturographic data
K-Force Plates (Kinvent) will allow us to assess both static and dynamic balance in order to objectively evaluate postural control, stability, and asymmetries.
Time frame: At baseline and endline of intervention (week 1 and 4)
Height
Height will me measured and expressed in centimeters.
Time frame: At baseline and endline of intervention (Week 1 and 14)
Weight
Weight in kilograms will be measured using a Tanita scale.
Time frame: At baseline and endline of intervention (Week 1 and 14)
Body fat percentage
Body fat percentage (in percent) will be measured using a Tanita scale.
Time frame: At baseline and endline of intervention (Week 1 and 14)
Body mass index
BMI (in kilograms per square meters) will be measured using the height and the weight (H/W\^2).
Time frame: At baseline and endline of intervention (Week 1 and 14)
Heart rate
Heart rate (in percent of max heart rate) will be analyzed during each training session
Time frame: Throughout the entire intervention (week 2 to week 13)
Rating of perceived exertion
RPE (in arbitrary unit) will be evaluated using the Borg scale after each training session. Borg scale ranges from 6 (no exertion) to 20 (extremely hard).
Time frame: Throughout the entire intervention (week 2 to week 13)
Mental demand
Mental demand of the training (in arbitrari unit) will be evaluated using a modified Borg scale after each training session. Modified Borg scale ranges from 0 (no exertion) to 10 (extremely hard).
Time frame: Throughout the entire intervention (week 2 to week 13)
Muscle soreness
Muscle soreness (in arbitrary unit) will be evaluated using a visual analog scale before each training session. This scale ranges from 0 (no pain) to 10 (worst pain possible).
Time frame: Throughout the entire intervention (week 2 to week 13)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 9 months is below that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.